上海莱士血液制品股份有限公司 2024 年第三次临时股东大会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在增加、变更、否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议； 证券代码：002252 证券简称：上海莱士 公告编号：2024-063 3、本次会议提案涉及股东大会特别决议事项，按照《公司章程》规定，本次特 别决议事项需经出席会议股东（包括股东代理人）所持表决权 3/4 以上表决同意后方 可通过。 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间为：2024 年 8 月 29 日（星期四）14:00； 网络投票时间为：2024 年 8 月 29 日（星期四）； 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 8 月 29 日的交易时间，即 9:15－9:25，9:30－11:30，13:00－15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2024 年 8 月 29 日 9:15 至 15:00 期间的任意时 间。 2、现场会议召开 ...

关于上海莱士血液制品股份有限公司 2024 年第三次临时股东大会的 法律意见书 北京市中伦（上海）律师事务所 二〇二四年八月 法律意见书 北京市中伦（上海）律师事务所 关于上海莱士血液制品股份有限公司 2024 年第三次临时股东大会的 法律意见书 致：上海莱士血液制品股份有限公司（以下简称"公司"） 北京市中伦（上海）律师事务所（以下简称"本所"）接受公司的委托，指 派律师出席并见证公司2024年第三次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 （以下简称"《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》 （以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业 规则（试行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政 法规、规章、规范性文件及《上海莱士血液制品股份有限公司章程》（以下简称 "《公司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、出席 会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律 ...

Investment Rating - The investment rating for the company is upgraded to "Buy" [1] Core Views - The company is experiencing steady growth and is entering a new high-quality development cycle [1] - The company reported a total revenue of 4.252 billion yuan for the first half of 2024, representing a year-on-year increase of 9.02%, with a net profit attributable to shareholders of 1.241 billion yuan, up by 0.15% [1] - The company’s gross margin is 40.88%, and the net profit margin is 29.19% [1] - The company has a leading position in the industry, and with Haier Group becoming the controlling shareholder, it is expected to continue to receive support and synergies that will enhance its performance [1][2] Financial Performance Summary - For the first half of 2024, the company achieved revenue of 2.196 billion yuan, an increase of 19.51%, and a net profit of 484 million yuan, a decrease of 7% [1] - The company’s main non-operating income includes a one-time government subsidy of 33.33 million yuan and investment income from financial assets amounting to 179 million yuan [1] - The company’s self-produced albumin, imported albumin, immunoglobulin, and other blood products generated revenues of 800 million, 1.955 billion, 839 million, and 607 million yuan respectively, with year-on-year growth rates of 17.21%, 18.87%, -15.50%, and 15.69% [1] - The company’s gross margins for these products were 46.21%, 17.86%, 58.73%, and 83.31% respectively [1] Future Projections - The company is projected to achieve total revenue of 8.538 billion yuan in 2024, 9.678 billion yuan in 2025, and 10.914 billion yuan in 2026, with year-on-year growth rates of 7.2%, 13.4%, and 12.8% respectively [2] - The net profit attributable to shareholders is expected to reach 2.292 billion yuan in 2024, 2.603 billion yuan in 2025, and 2.937 billion yuan in 2026, with growth rates of 28.8%, 13.6%, and 12.8% respectively [2] - The company’s gross margin is expected to remain stable around 40.6% in 2024, with slight improvements in subsequent years [2] Cash Flow and Financial Ratios - The operating cash flow for 2024 is projected to be 1.537 billion yuan, with a net profit of 2.292 billion yuan [4] - The company’s P/E ratio is expected to decrease from 29.63 in 2024 to 16.18 in 2026, indicating improved valuation over time [5] - The return on equity (ROE) is projected to increase from 7.2% in 2024 to 7.8% in 2026 [5]

Group 1: Company Overview - Shanghai Laishi Blood Products Co., Ltd. is now under the control of Haier Group as of July 2024, which will provide comprehensive support for the company's long-term and stable development [3] - The company emphasizes research and development, achieving several domestic "firsts" in innovative breakthroughs, including the first virus-inactivated human coagulation factor product [3] - The company is advancing the clinical trial of the world's first monoclonal antibody treatment for hemophilia, SR604 injection, which received clinical approval in March 2024 [3] Group 2: Financial Performance - In the first half of 2024, the company reported an investment income of 158 million yuan from GDS, calculated at a 45% investment ratio [5] - The gross profit margin for self-produced albumin was 46.21%, an increase of 1.63% compared to the same period last year; for self-produced immunoglobulin, it was 58.73%, up by 2.15% [5] - Other self-produced products had a gross profit margin of 83.31%, which decreased by 1.64% year-on-year [5] Group 3: Market and Product Insights - The growth of plasma collection is influenced by various factors, including the operational management capabilities of plasma stations and local population characteristics [4] - The company is focusing on both existing and new plasma sources, enhancing management for internal growth while also pursuing acquisitions and new plasma station constructions [4] - The pricing of blood products is primarily affected by procurement policies in hospitals and supply-demand relationships in the external market [4] Group 4: Strategic Partnerships - A new exclusive strategic cooperation agreement has been established with Kliber, covering all current and future business operations in the fields of bioscience and diagnostics in China [3] - Kliber has committed to ensuring that GDS's cumulative EBITDA during the evaluation period from January 1, 2024, to December 31, 2028, will not be less than 850 million USD [4]

Investment Rating - The report maintains a "Recommended" rating for Shanghai Laishi, with a projected market capitalization of 625 billion yuan based on the recent transaction of selling 20% of its shares for 125 billion yuan [2]. Core Views - The company reported a revenue of 4.252 billion yuan for the first half of 2024, a year-on-year increase of 9.02%, while the net profit attributable to shareholders was 1.241 billion yuan, a slight increase of 0.15%. The investment net income saw a significant rise of 69% to 340 million yuan [1][2]. - The revenue growth in Q2 2024 was driven by strong sales of albumin and factor products, despite a decline in the sales of immunoglobulin [1]. - The gross margin slightly decreased due to an increase in the proportion of low-margin products and currency fluctuations, with a gross margin of 41% for H1 2024, down 2 percentage points year-on-year [1]. Financial Performance Summary - For H1 2024, the revenue from imported albumin was 1.955 billion yuan, up 18.87%, accounting for 46% of total revenue, with a gross margin of 17.86%, down 2 percentage points [1]. - The revenue from self-produced albumin was 800 million yuan, up 17.21%, with a gross margin of 46.21%, an increase of 2 percentage points [1]. - The revenue from immunoglobulin decreased by 15.50% to 839 million yuan, while the revenue from other blood products increased by 15.69% to 607 million yuan [1]. - The management expense ratio increased in the short term, while the sales and R&D expense ratios remained stable [1]. - The company forecasts revenues of 8.640 billion yuan, 9.587 billion yuan, and 10.627 billion yuan for 2024, 2025, and 2026 respectively, with net profits projected at 2.198 billion yuan, 2.527 billion yuan, and 2.914 billion yuan for the same years [3].

2024/6/30 | 期 | 末 | 数 | 期 | 初 | 数 | 期 | 末 | 数 | 期 | 初 | 数 | 项 | 项 | 目 | 目 | 合 | 并 | 母 | 公司 | 合 | 并 | 母 | 公司 | 合 | 并 | 母 | 公司 | 合 | 并 | 母 | 公司 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ...

关于 2024 年中期利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）于 2024 年 8 月 26 日召开第六届 董事会第三次会议及第六届监事会第二次会议，审议通过了《2024 年中期利润 分配方案》等，根据《公司法》、中国证监会《上市公司监管指引第 3 号—上市 公司现金分红》、深圳证券交易所《上市公司自律监管指引第 1 号—主板上市公 司规范运作》等相关法律、法规、规范性文件及《公司章程》的规定，为进一步 提高分红频次，增强投资者回报水平，结合公司实际情况，制定 2024 年中期利 润分配方案如下： 证券代码：002252 证券简称：上海莱士 公告编号：2024-061 上海莱士血液制品股份有限公司 公司拟定的2024年半年度利润分配方案为：拟以分红派息股权登记日总股本 （扣除公司回购专用证券账户持有公司股票）为基数，向全体股东每10股派发现 金股利0.37元人民币（含税）。若公司以6,635,984,837股（目前总股本6,637,984,837 股扣除回购专用证券账户持有的股票2,000,0 ...

关于第六届董事会第三次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）第六届董事会第三次会议于 2024 年 8 月 16 日以电话和邮件方式发出会议通知，并于 2024 年 8 月 26 日上午 9 点 以通讯方式召开。 本次会议应出席董事 9 名，实际出席董事 9 名。本次会议由公司董事长谭丽 霞女士召集和主持。会议的召集、召开与表决程序符合《公司法》和《公司章程》 等有关规定。会议在保证所有董事充分发表意见的前提下，全体与会董事经投票 表决，一致作出如下决议： 证券代码：002252 证券简称：上海莱士 公告编号：2024-057 上海莱士血液制品股份有限公司 根据公司 2024 年半年度财务报告（未经审计），公司 2024 年半年度实现净 1 利润为 777,832,264.27 元（母公司报表），2024 年半年度合并报表中归属于上市 公司股东的净利润为 1,240,798,423.17 元，截至 2024 年 6 月 30 日，公司实际可 供股东分配的利润为 4,393,749,578.33 ...

证券代码：002252 证券简称：上海莱士 公告编号：2024-058 上海莱士血液制品股份有限公司 1、审议通过了《2024 年半年度报告全文及摘要》 经审核，监事会认为：董事会编制和审核公司2024年半年度报告全文及摘要 的程序符合法律、行政法规和中国证券监督管理委员会的相关规定，报告内容真 实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。 表决结果：3 票同意，0 票弃权，0 票反对。 《2024 年半年度报告》全文刊登于巨潮资讯网（www.cninfo.com.cn），《2024 年半年度报告摘要》同时刊登于《证券时报》、《中国证券报》、《上海证券报》、 《证券日报》和巨潮资讯网（www.cninfo.com.cn），供投资者查阅。 2、审议通过了《2024年半年度募集资金存放与使用情况的专项报告》 表决结果：3 票同意，0 票弃权，0 票反对。 1 关于第六届监事会第二次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）第六届监事会第二次会议于 2024 年 ...

上海莱士血液制品股份有限公司 监事会关于第六届监事会第二次会议相关事项的书面审核 意见 一、监事会对2024年半年度报告的书面审核意见 公司第六届监事会第二次会议对《上海莱士血液制品股份有限公司2024年半 年度报告全文及摘要》进行认真审核。经审核，监事会认为： 董事会编制和审核公司2024年半年度报告全文及摘要的程序符合法律、行政 法规和中国证券监督管理委员会的相关规定，报告内容真实、准确、完整地反映 了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 二、监事会对2024年中期利润分配方案的书面审核意见 公司第六届监事会第二次会议就《2024 年中期利润分配方案》进行了认真 审核，认为： 根据公司 2024 年半年度财务报告（未经审计），公司 2024 年半年度实现净 利润为 777,832,264.27 元（母公司报表），2024 年半年度合并报表中归属于上市 公司股东的净利润为 1,240,798,423.17 元，截至 2024 年 6 月 30 日，公司实际可 供股东分配的利润为 4,393,749,578.33 元（母公司报表），合并报表实际可供股东 分配的利润为 9,360,6 ...